European regulator launches review of recalled heart drug

August 2, 2018

The European Medicines Agency (EMA) said Thursday it is conducting a review of the health effects on patients of a widely used blood pressure medication recalled around the world last month.

The regulator will analyse the impact of active ingredient valsartan, produced by Chinese manufacturer Zhejiang Huahai Pharmaceutical Company, after warnings of contamination by a cancer-causing impurity.

The company, listed on the Shanghai stock exchange, launched a global recall of the drug on July 18 following warnings by US and European regulators over the presence of N-nitrosodimethylamine (NDMA), which is believed to potentially cause cancer through long-term use.

In a series of pronouncements last month, Huahai said it had moved to suspend supply and had begun the recall.

Valsartan is a generic drug mainly used for treatment of high and .

NDMA was an unexpected impurity believed to have formed as a side product after Huahai introduced changes to its manufacturing process in 2012, according to the London-based EMA.

It first issued an alert over the drug on July 5, and American regulators followed up with their own a week later.

The EMA repeated Thursday that there was "no immediate risk to patients" and they "should not stop taking their medicines without consulting their doctor or pharmacist".

The EMA said its review is being carried out by the Committee for Medicinal Products for Human Use, which is responsible for probing concerns over patient medicines.

Its opinion will be forwarded to the European Commission, which will issue a final legally binding decision applicable in all countries in the EU.

Huahai's stock has dropped more than 20 percent since the warnings first emerged in early July.

The company could not be reached for immediate comment on Thursday.

Explore further: Chinese firm recalls heart drug as US, EU raise concerns

Related Stories

Chinese firm recalls heart drug as US, EU raise concerns

July 18, 2018
The Chinese manufacturer of a widely used blood pressure medication said it had launched a global recall after US and European regulators warned of contamination by a cancer-causing impurity.

Affected by the valsartan heart drug recall? here's what to do

July 19, 2018
(HealthDay)—After the U.S. Food and Drug Administration announced last week that certain brands of blood pressure medicines contained a carcinogen and were being recalled, many patients may wonder what's next for their ...

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

China's persistent food and drug safety problem

July 24, 2018
Chinese authorities are scrambling to defuse public outrage over a safety scandal involving rabies vaccines, just one of a string of food and drug scares to hit the country in recent years.

Novartis drug investigated after 11 deaths

January 20, 2012
A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died.

US approves Sanofi, Regeneron arthritis drug

May 23, 2017
US federal regulators have given the green light to French pharmaceutical company Sanofi and its US partner Regeneron to market a drug to treat the chronic inflammatory condition, rheumatoid arthritis.

Recommended for you

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

Do price spikes on some generic drugs indicate problems in the market?

October 1, 2018
A new USC study reports that sudden price spikes for some generic drugs—such as the recently reported increases of a decades-old generic heart medication and an antibiotic—are becoming more common.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.